Weave Bio has secured $10 million in funding to accelerate its mission of streamlining regulatory processes for pharma and biotech. Its AI-powered platform, starting with AutoIND, automates and accelerates the IND submission process, reducing preparation time by over 50% and potentially bringing new therapies to patients faster while lowering development costs.
Press release
Weave Bio AI secures $10 million in funding
Related news
Press release
Weave Bio Launches HAQ Manager, Extending AI-Native Regulatory Automation into Critical Review Phase
Press release
Weave Bio secures $20M Series A funding to enhance its AI-native regulatory platform
Press release
Parexel announces AI partnership with Weave Bio to accelerate regulatory submission processes
Press release